Filing Details

Accession Number:
0000899243-21-007232
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-18 20:44:22
Reporting Period:
2021-02-16
Accepted Time:
2021-02-18 20:44:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1645460 Cue Biopharma Inc. CUE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1571862 Kenneth Pienta C/o Cue Biopharma, Inc.
21 Erie Street
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-16 16,000 $2.86 18,000 No 4 M Direct
Common Stock Disposition 2021-02-16 16,000 $15.15 2,000 No 4 S Direct
Common Stock Acquisiton 2021-02-17 1,280 $2.86 3,280 No 4 M Direct
Common Stock Acquisiton 2021-02-17 2,994 $5.00 6,274 No 4 M Direct
Common Stock Disposition 2021-02-17 4,274 $15.06 2,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-02-16 16,000 $0.00 16,000 $2.86
Common Stock Stock Option (right to buy) Disposition 2021-02-17 1,280 $0.00 1,280 $2.86
Common Stock Stock Option (right to buy) Disposition 2021-02-17 2,994 $0.00 2,994 $5.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,280 2023-11-16 No 4 M Direct
0 2023-11-16 No 4 M Direct
147,006 2024-04-17 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.60, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.
  4. The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017.
  5. The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017.